MOFO PA #EIGHT

RECEIVED CENTRAL FAX CENTER

2001

AUG 2 1 2006

MORRISON

FOERSTER

755 PAGE MILL ROAD PALO ALTO CALIFORNIA 94304-1018

TELEPHONE: 650.813.5600 FACSIMILE: 650.494.0792

www.mofo.com

MORRISON & FOERSTER LLP

NEW YORK, SAN PRANCISCO, LOS ANGELES, PALO ALTO, SAN DIEGO, WASHINGTON, D.C.

DENVER, NORTHERN VIRGINIA, ORANGE COUNTY, SACRAMENTO, WALNUT CREEK, CENTURY CITY

TOKYO, LONDON, BEIJING, SHANGHAI, HONG KONG, SINGAPORB, BRUSSELS

To:

NAME:	FACSIMILE:	TELEPHONE:
Commissioner for Patents U.S. Patent and Trademark Office	(571) 273-8300	(571) 272-4000

FROM:

Kimberly A. Bolin

DATE:

August 21, 2006

Registration No. 44,546

Number of pages	12	
with cover page:		

Preparer of this slip has confirmed that facsimile number given is correct: 12056/eag4

Comments:

Attorney Docket No.: 420052000117

Group Art Unit: 1615 Examiner: G. Kishore

Application No.: 09/628,387 Filing Date: August 1, 2000

Inventors: Patrick SOON-SHIONG et al.

Title: METHODS AND FORMULATIONS OF TAXANES

Papers attached:

- 1. Transmittal Form (1 page)
- 2. Power of Attorney (1 page)
- 3. Statement under 37 CFR 3.73(b) (1 page)
- 4. Copy of Assignment (3 pages)
- 5. Copy of Certificate of Amendment (2 pages)
- 6. Copy of Certificate of Merger (3 pages)

To ensure compliance with requirements imposed by the United States Internal Revenue Service, Morrison & Foerster LLP informs you that, if any advice concerning one or more U.S. Federal tax issues is contained in this facsimile (including any attachments), such advice is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.

CAUTION - CONFIDENTIAL

This facsimile contains confidential information that may also be privileged. Unless you are the addressee (or authorized to receive for the addressee); you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

pa-1088616

RECEIVED CENTRAL FAX CENTER

AUG 2 1 2006

PTO/SB/21 (09-04)

	Approved for use through 07/31/2008. OMB 0651-0031
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI
Under the Described Reduction Act of 1995, no persons are required to respi	and to a collection of information unless it displays a valid OMB control number

Application Number 09/628.387 Filing Date TRANSMITTAL August 1, 2000 First Named Inventor Patrick SOON-SHIONG FORM Art Unit 1615 (to be used for all correspondence after initial filing) Examiner Name G. Kishore Attorney Docket Number 420052000117 11 Total Number of Pages in This Submission ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to TC Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petitlon Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address (1 page) Other Enclosure(s) (please Terminal Disclaimer **Extension of Time Request** Identify below): - Statement under 37 CFR 3.73(b) (1 **Express Abandonment Request** Request for Refund page) Copy of Assignment (3 pages) CD, Number of CD(s) - Copy of Certificate of Amendment Information Disclosure Statement (2 pages) Copy of Certificate of Merger (3 pages) Certified Copy of Priority Landscape Table on CD - Facsimile Cover Sheet Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name MORRISON & FOERSTER LLP (Customer Number 25226) Signature Printed name Kimbeny A. Bolin Reg. No. Date 44.546 August 21, 2006 I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below. Dated: August 21, 2008 (Elsa Guezlec)

pa-1088612

PTO/SB/80 (01-06)
Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless & displays a valid OMB control number.

	POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO				JSPTO	
I hereby revo	I hereby revoke all previous powers of attorney given in the application identified in the attached statement under				ement under	
I hereby app						
OR	x Practitioners associated with the Customer Number:		20220			
Practitio	ner(s) named below (if more the	han ten patent prac	titioners are to be nam	ed, then a cu	ustomer number n	nust be used):
	Name	Registration Number		Name		Registration Number
	•	1			ł	l
as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b). Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to: X The address associated with Customer Number: 25226						
OR Firm or Individual Name Address						
City		State		Zip		
Country		Telephone		Email		
Assignee Name and Address: Abraxis BioScience, Inc. 2730 Wilshire Boulevard, Suite 500 Santa Monica, California 90403						
A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.						
SIGNATURE of Assignee of Record The individual whose signature and title is supplied below is authorized to act on behalf of the assignce						
Signature						
Name	Richard E. Maroun		Teleph	_=	(310) 883	-3146
Title	y to the contract of the contr			_		

Attorney Docket No.: 420052800100

PTO/SB/96 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid Owle conflict number STATEMENT UNDER 37 CFR 3.73(b)			
Applicant/Patent Ow	mer. Patrick SOON-SHIONG et a	1.	
Application No./Pate	ent No.: 09/628,387	Filed/Issue Date: August 1, 2000	
Entitled: METHO	DDS AND FORMULATIONS OF TAX	ANES	
Abraxis BioScience, Inc. , a corporation (Name of Assignee) (Type of Assignee, e.g., corporation, pertnership, university, government agency, etc.)			
states that it is:		·	
1. X the assign	nee of the entire right, title, and intere	est; or	
2. an assign	nee of less than the entire right, title a	and interest.	
The exter	nt (by percentage) of its ownership int	terest is %	
in the patent applica	tion/patent identified above by virtue	of either:	
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, or for which a copy thereof is attached.			
OR	, , o , , , ,		
B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:			
	Neil P. DESAl and Patrick SOON- SHIONG	To: VivoRx Pharmaceuticals, Inc.	
The d		States Patent and Trademark Office at	
Reel	, Frame	, or for which a copy thereof is attached.	
2. From:	VivoRx Pharmaceuticals, Inc.	To: American BioScience, Inc.	
		States Patent and Trademark Office at	
Reel	, Frame	, or for which a copy thereof is attached.	
3. From:	American BioScience, Inc.	To: Abraxis BioScience, Inc.	
		States Patent and Trademark Office at	
Reel	, Frame	, or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet.			
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]			
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.			
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		8.12.05	
L	Signature	Date	
Richard E. Maroun (310) 883-3146			
Printed or Typed Name Telephone Number			
Chief Administrative Officer			
	Title		

Attorney Docket No.: 420052000117

ASSIGNMENT



This Assignment is made by Neil P. Desai, Los Angeles, California and Patrick Soon-Shiong, Los Angeles, California ssignor(s), to, VIVORX PHARMACEUTICALS, INC., Assignee, having a place of business at 2825 Santa Monica Blvd., Suite 104, Santa Monica, California 90404.

WHEREAS, Assignor(s) have invented a new and useful invention entitled COMPOSITIONS USEFUL FOR ADMINISTRATION OF CHEMOTHERAPEUTIC AGENTS, for which an application for United States Letters Patent, was filed on September 9, 1997 in the United States Patent and Trademark Office and assigned U.S. Serial No.08/926,155.

WHEREAS, Assignor(s) believe themselves to be the original inventor(s) of the invention disclosed and claimed in said application for Letters Patent; and

WHEREAS, the parties desire to have a recordable instrument assigning the entire right, title and interest in and to said invention, said application and any Letters Patent that may be granted for said inventions in the United States and throughout the world,

NOW, THEREFORE, in accordance with the obligations to assign the invention and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor(s) sell(s), assign(s), and transfer(s) to Assignee, the entire right, title, and interest in and to said invention, said application and any Letters Patent that may be granted for said invention in the United States and throughout the world, including the right to file foreign applications directly in the name of the Assignee and to claim for any such foreign applications any priority rights to which such applications are entitled under international conventions, treaties, or otherwise.

Assignor(s) agree that, upon request and without further compensation, but at no expense to Assignor(s), they and their legal representatives and assign(s) will do all lawful acts, including the execution of papers and the giving of testimony, that may be necessary or desirable for obtaining, sustaining, reissuing, or enforcing Letters Patent in the United States and throughout the world for said invention, and for perfecting, recording, or maintaining the title of

2

Assignee, its successors and assigns, to said invention, said application, and any Letters Patent granted for said invention in the United States and throughout the world.

Assignor(s) represent and warrant that they have not granted and will not grant to others any rights inconsistent with the rights granted herein.

Assignor(s) authorize(s) and request(s) the Assistant Commissioner for Patents of the United States and of all foreign countries to issue any Letters Patent granted for said invention, whether on said application or on any subsequently filed division, continuation, continuation-in-part or reissue application, to Assignee, its successors and assigns, as the assignee of the entire interest in said invention.

3

IN WITNESS WHEREOF, Assignor(s) have executed this Assignment on the date(s) provided below.

Signature 7,1998 before me, and for said State, personally appeared Neile Desai, proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/ske/they executed the same in his/her/their authorized capacity(jes), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. WITNESS my hand and official seal. CAROL S. RIGSBEE Comm. # 1168326 OTARY PUBLIC-CALIFORMA Los Angeles County (Signature of Notary Assignor: Hatrick Soon-Shiong Signature 1998 before me, <u>Carol</u> and for said State personally appeared farick Son Stie proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to m e that he/she/they executed the same in his/he/their authorized capacity(jes), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

(Signature of Notary)

102811-990000



CERTIFICATE OF AMENDMENT OF ARTICLES OF INCORPORATION OF VIVORX PEIARMACEUTICAL, INC., * California corporation

EMDORSED - FILED IN THE OFFICE OF THE

APR 10 1998

BILL JONES. SECRETARY OF STATE

Patrick Soon-Shiong hereby certifies as follows:

- He is the President and Secretary of VivoRx Pharmaceutical, Inc., a California corporation.
- ARTICLE I of the Articles of Incorporation of this corporation is amended to read in full as set forth below:

The name of this corporation is American BloScience, Inc."

- The amendment set forth above in Section 2 of this certificate (the "Amendment") has been duly approved by the Board of Directors of this corporation.
- The Amendment has been duly approved by the required vote of the shareholders of this corporation in accordance with Section 992 of the California Corporations Code. This corporation has two series Preferred Stock and one class of Common Stock, all of which votes together as one class, and the number of outstanding shares entitled to vote with respect to the Amendment is 48,105,369. The number of shares voting in favor of the Amendment equaled or exceeded the vote required. The percentage vote required for the approval of the Amendment was more than fifty percent (50%).


The undersigned hereby declares under penalty of perjury under the laws of the State of California that he has read this certificate, knows the contents thereof, and that the same is igue and correct of his own knowledge.

California on April 9, 1998.



DWW.GETMINGSELS.LANDS

- C



I, BILL JONES, Secretary of State of the State of California, hereby certify:

That the attached transcript has been compared with the record on file in this office, of which it purports to be a copy, and that it is full, true and correct.

IN WITNESS WHEREOF, I execute this certificate and affix the Great Seal of the State of California this

APR 1 4 1998



Bill Jones

Secretary of State

97 55085





The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"AMERICAN BIOSCIENCE, INC", A CALIFORNIA CORPORATION,

WITH AND INTO "AMERICAN PHARMACEUTICAL PARTNERS, INC." JUNDER THE NAME OF "ABRAXIS BIOSCIENCE, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE EIGHTEENTH DAY OF APRIL, A.D. 2006, AT 9 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

3430252 8100M

060361520

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 4676633

DATE: 04-19-06

State of Delaware Secretary of State Division of Corporations Delivered 09:04 PM 04/18/2006 FILED 09:00 PM 04/18/2006 SRV 060361520 - 3430252 FILE

CERTIFICATE OF MERGER

OF

AMERICAN BIOSCIENCE, INC.

INTO

AMERICAN PHARMACEUTICAL PARTNERS, INC.

Under Section 252 of the Delaware General Corporation Law ("DGCL")

The undersigned American Pharmaceutical Partners, Inc., a Delaware corporation (the "Company"), DOES HEREBY CERTIFY:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

Name

State of Incorporation

American BioScience, Inc.

California

American Pharmaceutical Partners, Inc.

Delaware

SECOND: That so agreement and plan of merger between the Company and American BioScience, Inc., dated November 27, 2005 (the "Merger Agreement"), has been approved, adopted, executed and acknowledged by each of the constituent corporations in accordance with Section 252 of the General Corporation Law of the State of Delaware.

THIRD: The Company shall be the surviving corporation of the merger (the "Surviving Corporation"). At the effective time of the merger, the name of the Surviving Corporation will be amended to be Abraxis Bioscience, Inc. as set forth in Article Fourth.

FOURTH: The Amended and Restated Certificate of Incorporation of the Company shall be the Certificate of Incorporation of the Surviving Corporation, with such Amended and Restated Certificate of Incorporation being amended as follows:

(a) Section 1 of the Amended and Restated Certificate of Incorporation is amended to read in its entirety as follows:

Section 1

The name of the corporation is Abraxis BioScience, Inc. (the "Corporation")."

- (b) Section 4.1 of the Amended and Restated Certificate of Incorporation is amended to read in its entirety as follows:
- "4.1 The aggregate number of shares of capital stock which the Corporation shall have authority to issue is 356,000,000, consisting of 350,000,000 shares of common stock, \$.001 par value per share ("Common Stock"), and 6,000,000 shares of preferred stock \$.001 par value per share ("Preferred Stock")."

Cartificate of Margar_v1

FIFTH: The executed Merger Agreement is on file at an office of the Surviving Corporation at 1501 East Woodfield Road, Suite 300 East, Schaumburg, Illinois 60173-5837.

SIXTH: A copy of the Merger Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of any constituent corporation.

SEVENTH: The authorized capital stock of American BioScience, Inc., the only constituent corporation which is not a Delaware corporation, is 300,000,000 shares of common stock and 32,500,000 shares of preferred stock.

Dated: April 💆 2006

Ø

AMERICAN PHARMACEUTICAL PARTNERS, INC.

Name: Fatrick Soon-Shiong Title: Chief Executive Officer